| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, Bethesda, Maryland 20892
Bipolar affective disorder is a common, severe, chronic, and often life-threatening illness, associated with other medical and psychiatric conditions (i.e., co-morbidity). The treatment of this devastating disorder was revolutionized by the discovery of lithium’s antimanic effects over fifty years ago. Recent molecular and cellular biological studies have identified a number of unexpected targets for this monovalent cation, notably glycogen synthase kinase-3 and neurotrophic signaling cascades. These findings are leading to a reconceptualization of the biological underpinnings of bipolar disorder and are resulting in considerable interest in utilizing lithium for the treatment of certain neurodegenerative disorders. We review recent insights into lithium’s actions including its direct inhibitory actions on inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3, fructose 1,6-bisphosphatase, bisphosphate nucleotidase, and phosphoglucomutase enzymes. We also discuss lithium’s intracellular downstream targets including adenylate cyclase, the phosphoinositol cascade (and its effect on protein kinase C), arachidonic acid metabolism, and effects on neurotrophic cascades. Many of the new insights of lithium’s actions may lead to the strategic development of improved therapeutics for the treatment of bipolar disorder.
This article has been cited by other articles:
|
|
 |
|
  R. H. Perlis, J. W. Smoller, M. A.R. Ferreira, A. McQuillin, N. Bass, J. Lawrence, G. S. Sachs, V. Nimgaonkar, E. M. Scolnick, H. Gurling, et al. A Genomewide Association Study of Response to Lithium for Prevention of Recurrence in Bipolar Disorder Am J Psychiatry, June 1, 2009; 166(6): 718 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yildiz, D. Ongur, and P. Renshaw Concomitant Use of Lorazepam With Tamoxifen in Bipolar Mania Clinical Trials--Reply Arch Gen Psychiatry, January 1, 2009; 66(1): 108 - 109. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hirota, W. G. Lewis, A. C. Liu, J. W. Lee, P. G. Schultz, and S. A. Kay A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3{beta} PNAS, December 30, 2008; 105(52): 20746 - 20751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yildiz, S. Guleryuz, D. P. Ankerst, D. Ongur, and P. F. Renshaw Protein Kinase C Inhibition in the Treatment of Mania: A Double-blind, Placebo-Controlled Trial of Tamoxifen Arch Gen Psychiatry, March 1, 2008; 65(3): 255 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-F. Lin, C.-L. Chen, C.-W. Chiang, M.-S. Jan, W.-C. Huang, and Y.-S. Lin GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis J. Cell Sci., August 15, 2007; 120(16): 2935 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ohnishi, H. Ohba, K.-C. Seo, J. Im, Y. Sato, Y. Iwayama, T. Furuichi, S.-K. Chung, and T. Yoshikawa Spatial Expression Patterns and Biochemical Properties Distinguish a Second myo-Inositol Monophosphatase IMPA2 from IMPA1 J. Biol. Chem., January 5, 2007; 282(1): 637 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Chen, C.-F. Lin, C.-W. Chiang, M.-S. Jan, and Y.-S. Lin Lithium Inhibits Ceramide- and Etoposide-Induced Protein Phosphatase 2A Methylation, Bcl-2 Dephosphorylation, Caspase-2 Activation, and Apoptosis Mol. Pharmacol., August 1, 2006; 70(2): 510 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Zhang, J. Zou, Q. Bao, W.-L. Chen, L. Wang, H. Yang, and C.-C. Zhang A Lithium-Sensitive and Sodium-Tolerant 3'-Phosphoadenosine-5'-Phosphatase Encoded by halA from the Cyanobacterium Arthrospira platensis Is Closely Related to Its Counterparts from Yeasts and Plants Appl. Envir. Microbiol., January 1, 2006; 72(1): 245 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Mechold, V. Ogryzko, S. Ngo, and A. Danchin Oligoribonuclease is a common downstream target of lithium-induced pAp accumulation in Escherichia coli and human cells. Nucleic Acids Res., January 1, 2006; 34(8): 2364 - 2373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Caskey and T. M. Pickett Disturbed calcium metabolism in a patient with bipolar disorder and impaired renal function Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1752 - 1755. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |
